PSA: What We Have Here Is A Failure to Innovate
Discussion at FDC/Windhover's annual Pharmaceutical Strategic Alliances gathering in New York reflected the urgent need for the industry to adopt new models in order to spur innovation--in R&D, finance, business development, and commercial operations.
You may also be interested in...
New data from Credit Suisse and Booz & Co. show that drug research is less novel and even more insular than it was in 2000, with lower percentages of novel targets and biologics in its pipeline. Moreover, Big Pharma has generally licensed less than it should. Nor has Big Pharma been particularly aggressive in copying Big Biotech's focus on developing a robust understanding of underlying disease biology-and reaping Big Biotech's higher approval rates. The cure: companies can significantly improve their odds of success through new approaches outside R&D (with payors, for example) and new capabilities in target selection and validation.
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers the potential for a return of the blockbuster
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers a possible a return of the blockbuster.